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Abstract: Heterozygous familial hypercholesterolemia (HeFH) creates elevated low-density lipoprotein cholesterol (LDL-C), causing premature atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend cascade screening relatives and starting statin therapy at 8–10 years old, but
adherence to these recommendations is low. Our purpose was to measure self-reported physician
practices for cascade screening and treatment initiation for HeFH using a survey of 500 primary care
physicians and 500 cardiologists: 54% “always” cascade screen relatives of an individual with FH, but
68% would screen individuals with “strong family history of high cholesterol or premature ASCVD”,
and 74% would screen a child of a patient with HeFH. The most likely age respondents would start
statins was 18–29 years, with few willing to prescribe to a pediatric male (17%) or female (14%).
Physicians who reported previously diagnosing a patient with HeFH were more likely to prescribe
to a pediatric patient with HeFH, either male (OR = 1.34, 95% CI = 0.99–1.81) or female (OR = 1.31,
95% CI = 0.99–1.72). Many physicians do not cascade screen and are less likely to screen individuals
with family history of known HeFH compared to “high cholesterol or premature ASCVD”. Most
expressed willingness to screen pediatric patients, but few would start treatment at recommended
ages. Further education is needed to improve diagnosis and treatment of HeFH.
Keywords: familial hypercholesterolemia; dyslipidemia; atherosclerosis; cascade screening; primary
prevention; cholesterol screening
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Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) that are
present from birth and predispose affected individuals to premature onset of atherosclerotic cardiovascular disease (ASCVD). In its heterozygous form (HeFH), it affects 1 in
200–300 individuals [1–5], making it the most common monogenic disorder and the most
common potentially fatal genetic disease in humans. Early treatment of FH correlates
directly with prevention of ASCVD and death [6–8]. Current HeFH treatment guidelines
from the National Lipid Association, the National Heart, Lung, and Blood Institute with
the American Academy of Pediatrics [9], and the American Heart Association [10] recommend initiation of medical therapy with a hydroxymethylglutaryl-CoA reductase inhibitor
(“statin”) starting as young as age 8.
HeFH screening recommendations are more controversial. Cascade screening children
from families with HeFH as young as 2 years of age is recommended by all current HeFH
guidelines [11–13]. However, universal cholesterol screening of all children to detect HeFH
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is recommended by the American Academy of Pediatrics [9], but was given a level of
evidence “I” (insufficient evidence to evaluate harms and benefits) from the United States
Preventive Services Task Force [14]. The 2018 Multi-Society guidelines for cholesterol
management assigned universal pediatric cholesterol screening a 2B recommendation,
implying the intervention “may be reasonable” and “effectiveness is unclear” [15]. Universal pediatric cholesterol screening has been shown to increase detection of HeFH [16]
but these guidelines are not well-recognized by physicians [17–19], which may lead to
under-recognition of HeFH in children and young adults.
In adults, studies evaluating clinician screening and treatment of hypercholesterolemia
have also yielded suboptimal results. In the US, 60% of young adults with a personal
history of high cholesterol reported having a cholesterol panel checked within the previous
5 years, and only 15% of 20–39-year-olds with severe hypercholesterolemia had been prescribed a statin [20]. When presented with a case example, fewer than 30% of cardiologists
correctly diagnosed HeFH [21]. The aim of our study was to measure physicians’ selfreported compliance with recommendations and knowledge regarding current evidence
supporting cascade screening of relatives potentially affected by HeFH, and for timing
of statin initiation in young adults and children. Although most cardiologists and many
primary care physicians (PCPs) do not directly treat pediatric patients, it is important
for them to be familiar with guidelines so they are able to recommend that children of
their adult patients with HeFH seek cholesterol screening from the child’s physician. We
hypothesized that the ability of cardiologists and PCPs to diagnose, treat, and cascade
screen patients with HeFH was poor.
2. Materials and Methods
The National Lipid Association surveyed 500 cardiologists and 500 PCPs (consisting
of family medicine, general medicine, and internal medicine specialties). The survey was
conducted from 29 August to 30 September 2019. Inclusion criteria included: currently
licensed and practicing within the United States, and self-report of having evaluated at least
one patient with baseline LDL-C ≥ 190 mg/dL. Physicians who reported certification by
the American Board of Clinical Lipidology or Accreditation Council for Clinical Lipidology
were excluded, as were physicians with a primary specialty of general pediatrics or a
pediatric subspecialty.
The survey was conducted online by MedSurvey (Southampton, PA, USA). Physicians
meeting eligibility criteria could complete the survey, and once the goal enrollment of
1000 physicians (500 PCPs and 500 cardiologists) was reached, the survey was closed. If
physicians met eligibility criteria based on a series of initial questions, they were invited to
continue with the survey and received a small honorarium for completing it. The eligibility
questions aimed to minimize geographical area bias within the United States. The study
used deidentified data and was deemed exempt from Institutional Board Review.
The survey consisted of 30 questions assessing physician demographics and recognition and treatment of HeFH (Table S1). All physicians self-reported whether or not
they routinely cared for individuals under 18 years of age. Likert scales were used to
measure the likelihood of screening first-degree family members and age at which cholesterol screening and statin treatment in patients with HeFH should begin. For respondents
indicating that they would not perform cholesterol screening in individuals under 18 years,
explanations were sought.
Survey data were collected and analyzed by the independent research partner, with
supplemental analysis by the authors. Categorical variables were compared between PCPs
and cardiologists using Chi-square test of proportions. Multiple logistic regression with
stepwise selection was also performed to examine whether provider type, region, practice
setting, or previous diagnosis of a patient with HeFH were independently associated with
intention to start a patient with HeFH under the age of 18 on a statin. This was analyzed
for all pediatric patients and separated into male and female patients under 18 years old.
A p-value < 0.15 was chosen for entry in the stepwise regression. When a final regression
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years old. A p-value < 0.15 was chosen for entry in the stepwise regression. When a final
regression model of predictors was constructed, those of borderline significance (0.05 < p
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individual with a strong family history of high cholesterol or premature ASCVD starting
Of PCPs 67% and of cardiologists 69% reported that they monitor LDL-C levels in an
between 18 and 29 years of age (p = 0.86) (Figure 1). For a patient with known HeFH, 54%
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Seventy-four percent of all respondents reported that they would recommend checking
cholesterol in a child of a patient with known HeFH, with physicians who reported caring
for pediatric patients more likely than those who do not to report screening in childhood
(86.9% vs. 65.9%, p < 0.001). However, only 7.3% of all respondents reported that they
would recommend screening children between 2 and 8 years of age, with respondents
caring for pediatric patients more likely to screen at this age (8.0% vs. 6.9%, p < 0.001)
(Figure 3).
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Figure 2. Frequency at which PCPs and cardiologists report recommending cascade screening for
a first-degree relative of a patient with HeFH. PCPs, primary care physicians; CDs, cardiologists.

Seventy-four percent of all respondents reported that they would recommend checking cholesterol in a child of a patient with known HeFH, with physicians who reported
caring for pediatric patients more likely than those who do not to report screening in
childhood (86.9% vs. 65.9%, p < 0.001). However, only 7.3% of all respondents reported
that they would recommend screening children between 2 and 8 years of age, with respondents
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Seventy-four percent of all respondents reported that they would recommend checking cholesterol in a child of a patient with known HeFH, with physicians who reported
caring for pediatric patients more likely than those who do not to report screening in
childhood (86.9% vs. 65.9%, p < 0.001). However, only 7.3% of all respondents reported
that they would recommend screening children between 2 and 8 years of age, with respondents caring for pediatric patients more likely to screen at this age (8.0% vs. 6.9%, p <
0.001) (Figure 3).
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ported that they cared for pediatric patients. For all 262 respondents, the most common
reason cited was lack of familiarity with pediatric cholesterol guidelines (75.6%). Respondents who reported that they care for pediatric patients were less likely than those who
do not care for pediatric patients to report lack of familiarity with pediatric cholesterol
guidelines, but were more likely to agree with the statements that “there is insufficient
Figure 3. Age at which PCPs and cardiologists recommend cascade screening for pediatric family members of a patient
evidence that screening children prevents ASCVD” and “there are no safe treatment options
with HeFH. PCPs, primary care physicians; HeFH, heterozygous familial hypercholesterolemia.
for high cholesterol in childhood” compared to respondents who do not report caring for
pediatric patients (Table 1).
Among the 262 respondents who would not screen until adulthood, 49 (18.7%) reported that they cared for pediatric patients. For all 262 respondents, the most common

cient evidence that screening children prevents ASCVD” and “there are no safe treatment
options for high cholesterol in childhood” compared to respondents who do not report
caring for pediatric patients (Table 1).
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Multiple logistic regression identified features that were associated with higher or
lower likelihood of prescribing a statin for pediatric patients overall, male patients, or
female patients (Table 2). No results but one reached statistical significance. PCPs were
somewhat less likely than cardiologists to prescribe a statin for a male patient but this was
not a factor for overall or female patients. Physicians practicing in the Southwest (compared
to Midwest) were less likely to consider prescribing a statin in a male pediatric patient,
however the clinical significance of this result is unclear. PCPs were less likely than cardiologists to consider prescribing a statin in a male patient with HeFH under age 18 (OR = 0.79,
95% CI = 0.61–1.02). Physicians who reported previously diagnosing any patient with
HeFH were more likely to prescribe a statin in male (OR = 1.34, 95% CI = 0.99–1.81) or
female (OR = 1.31, 95% CI = 0.99–1.72) patients under 18 years old.
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Table 2. Stepwise logistic regression analysis for factors associated with willingness to prescribe a statin for a pediatric
patient with HeFH. HeFH, heterozygous familial hypercholesterolemia; PCP, primary care physician; VA, Veterans Affairs;
LDL-C, low-density lipoprotein cholesterol.
Male or Female Patient

Male Patient Only

Female Patient Only

OR (95% CI)

Characteristic
PCP vs. Cardiologist

X

United States Region
Northeast vs. Midwest
Pacific vs. Midwest
Southeast vs. Midwest
Southwest vs. Midwest

X

Practice Location Description
Suburban vs. Rural
Urban vs. Rural

0.79 (0.61–1.02)

X

0.77 (0.52–1.15)
0.76 (0.50–1.15)
0.57 (0.38–0.86)
0.89 (0.58–1.36)

X

1.08 (0.71–1.65)
1.41 (0.91–2.18)

X

1.11 (0.73–1.70)
1.46 (0.94–2.26)

Practice Setting
VA/Government vs. Academic
Health system vs. Academic
Private vs. Academic
Other vs. Academic

X

X

X

Physician had previously diagnosed a
patient with LDL-C ≥ 190 mg/dL as
having HeFH

1.27 (0.96–1.68)

1.34 (0.99–1.81)

1.31 (0.99–1.72)

X denotes predictors applied to the stepwise regression model with p > 0.15 that were subsequently excluded.

4. Discussion
Our study shows that only 54% of surveyed cardiologists and PCPs would “always”
cascade screen a potentially affected first-degree adult relative of an individual with
HeFH, which is lower than the number that would monitor LDL-C in someone with “a
strong family history of high cholesterol or premature ASCVD”. The majority indicated
willingness to screen pediatric patients for HeFH, but very few reported screening at the
age recommended by guidelines or willingness to start treatment with a statin at ages
recommended by guidelines.
These findings demonstrate that these physicians surveyed are not recognizing that,
as an autosomal dominant disorder, first-degree relatives should be offered screening. This
lack of understanding regarding screening recommendations for HeFH is supported by
findings of previous studies [21–23]. In contrast, more (68%) would begin monitoring LDLC in young adults with “a strong family history” of premature ASCVD or high cholesterol,
but one third of PCPs and 31% of cardiologists would not start monitoring until a patient
was at least 30 years old. Ultimately, among the physicians surveyed, knowledge that their
patient had HeFH (as opposed to high cholesterol, with a family history of high cholesterol)
did not lead them to be more aggressive with cholesterol screening recommendations. This
contrast could be due either to a desire to focus care recommendations on the patient alone
(as opposed to making care recommendations for the patients’ family members who may
not be under their care) or due to a lack of understanding of HeFH inheritance patterns and
screening recommendations, or both. This result is consistent with a survey of physicians
in the United Kingdom, 50% of whom were not aware that familial hypercholesterolemia
has an autosomal dominant pattern of inheritance [24].
Agreement to cascade screen for pediatric relatives was different, however. Seventyfour percent of respondents indicated, when asked, that they would be willing to check
a cholesterol level in a child or would recommend a child get their cholesterol checked
if the child’s parent was their patient and had HeFH. Unsurprisingly, physicians who
report caring for pediatric patients were more likely to report that they would screen
during childhood. However, very few respondents (7.3% of all surveyed) had sufficient
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knowledge of pediatric FH recommendations to choose the correct age range during which
a pediatric patient with a HeFH parent should be screened (2 years old). Physicians
caring for children were slightly more likely to choose the correct age range compared to
physicians who did not care for children (8.0% vs. 6.9%, p < 0.001).
Among physicians who would not screen until adulthood, the most common cited
reason was lack of familiarity with pediatric cholesterol guidelines. These results further
support that physicians are generally unfamiliar with cascade screening recommendations
for HeFH. However, physicians who only care for adults are still obligated to understand
screening guidelines, so they are able to recommend that the children of their adult patients
with HeFH undergo cholesterol screening. The second most common reason cited was
“their children are not my patients”, furthering the idea that physicians may be motivated
by a desire to focus their care recommendations on their patient alone, and not make
recommendations for family members that are not under their direct care. This is consistent
with findings from another study [25].
Very concerning is that individuals who report caring for pediatric patients were
more likely to agree with the statement “the evidence showing that screening children [for
high cholesterol] prevents ASCVD is insufficient”. This may be due in part to conflicting
guidelines surrounding cholesterol screening for children. In 2011, the National Heart,
Lung, and Blood Institute released pediatric cardiovascular risk reduction guidelines that
recommended, among other items, that all children have a non-fasting cholesterol screen
performed between 9 and 11 years and again between 17 and 21 years old. This is in
addition to standard “selective screening” recommendations for children with high-risk
medical conditions or family history of high cholesterol or premature ASCVD [14]. These
guidelines were endorsed by the American Academy of Pediatrics. However, in 2016, the
United States Preventive Services Task Force updated their pediatric cholesterol screening
recommendation, giving it an “I” rating, indicating that the evidence was insufficient to
recommend for or against universal cholesterol screening [24]. Of note, this statement did
not address selective screening recommendations. These conflicting guidelines may lead
to lower rates of cholesterol screening and concern that evidence linking childhood high
cholesterol to adult ASCVD is lacking. Given the very strong evidence that cholesterol
levels in children and young adults predict the development of atherosclerosis, it is very
important that current medical practice takes this into account so that these individuals are
screened appropriately.
Similarly, individuals caring for pediatric patients were more likely to express concern
about treatment safety in childhood. This could reflect lack of knowledge about pediatric
statin safety data in general or a generalized concern about chronic medication use in
children. Conversely, it could represent in-depth knowledge of pediatric statin safety data,
which consistently shows safety and efficacy for short- and intermediate-length treatment
but is very limited beyond about 20 years of treatment [8]. Physicians who did not report
caring for pediatric patients were less likely to express this concern, either because they did
not have enough prior knowledge of pediatric treatment to have an opinion regarding the
subject, or they thought pediatric statin safety data were adequate. The lack of confidence
for treating children and young adults with a statin is concerning given current evidence
of the importance of LDL-C lowering as soon as possible given its known safety.
This study has important limitations. While our study was the largest survey of
physicians ever conducted on HeFH and has geographical representation within the US,
it is uncertain if survey respondents were representative of all primary care physicians
and cardiologists in the US. In particular, the sample of physicians who reported caring for
pediatric patients was limited. Respondents were selected if they answered yes to having
patients with LDL-C ≥ 190 mg/dL, and therefore, there is a possibility of bias among
participants with a specific interest in dyslipidemia, although those who self-identified
as lipid specialists were excluded from participation. Information on number of years in
practice, sex, or ethnicity of respondents was not available.
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5. Conclusions
Despite HeFH guidelines recommending cascade screening of potentially affected
relatives and starting affected individuals on statin therapy at 8–10 years old, many cardiologists and PCPs do not report routine cascade screening, nor screening for individuals with
a strong family history of premature ASCVD or high cholesterol. Those who see pediatric
patients are more likely to screen for HeFH but, conversely, have more concerns about the
benefit and safety of statin treatment in childhood. Just as concerning, very few indicated
willingness to start a pediatric patient with HeFH on a statin. More education is needed
among primary care physicians and cardiologists to recognize and treat HeFH and screen
family members, particularly pediatric family members. It may also be that education is
not enough to change physician behaviors and that innovative ways of actively changing
practices are needed.
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